FDA Approved

Get Zepbound Online — From $179/Month

Real Zepbound prescribed by licensed US clinicians. 20.9% avg at 15 mg body weight on average. FDA-approved tirzepatide brand for weight loss.

Start My Zepbound Evaluation — $179/mo → 60-Second Quiz

✓ No insurance needed · ✓ Ships in 5-7 days · ✓ Cancel anytime

Avg weight loss

20.9%

Cost

$1,069/mo

Dosing

Once weekly

FDA Status

Weight Loss

Zepbound is the FDA-approved tirzepatide brand for chronic weight management and obstructive sleep apnea. Approved in November 2023, Zepbound produces an average 20.9% body weight loss over 72 weeks at the 15 mg dose — currently the strongest results of any approved obesity medication.

Overview

Zepbound and Mounjaro are the same molecule — tirzepatide — but Zepbound is the brand name approved for weight loss (and, since 2024, for obstructive sleep apnea in obesity). It is administered as a once-weekly subcutaneous injection.

In 2025, Eli Lilly launched LillyDirect, a direct-to-consumer channel offering single-dose Zepbound vials at significantly reduced prices (from $349/mo) compared to the autoinjector pens ($1,069/mo).

How Zepbound Works

Zepbound is a dual GLP-1/GIP receptor agonist. It reduces appetite via central nervous system pathways, slows gastric emptying, and improves glucose metabolism. The dual mechanism (vs. semaglutide's single GLP-1 action) produces about 50% more weight loss in head-to-head comparisons.

Dosing & Schedule

Identical to Mounjaro: 2.5 mg starter, escalating every 4 weeks to 5, 7.5, 10, 12.5, and 15 mg. Most patients respond well at 10 or 12.5 mg.

Effectiveness — Trial Data

SURMOUNT-1 (72 weeks): 20.9% average weight loss at 15 mg. SURMOUNT-OSA (sleep apnea): significant reduction in apnea-hypopnea index in obese patients with moderate-severe OSA.

Side Effects

Same profile as Mounjaro: nausea (29-39%), diarrhea, constipation, vomiting. Most GI effects peak during titration and improve over time.

Cost — How Much Zepbound Costs in 2026

Zepbound pricing:

Autoinjector pens (list): $1,069/mo
LillyDirect vials: $349-499/mo (self-pay direct from Lilly)
Insurance copay: typically $25-150/mo
Lilly savings card: as low as $25/mo for commercially insured patients with coverage

Who Is Zepbound For?

Zepbound is appropriate for adults with BMI ≥30, or ≥27 with comorbidity. The 2024 OSA expansion adds adults with moderate-severe sleep apnea + obesity as an indication.

Zepbound Alternatives

Alternatives: Wegovy (semaglutide), compounded tirzepatide via telehealth, or Mounjaro for diabetes patients.

Frequently Asked Questions

Is Zepbound a GLP-1?

Zepbound (tirzepatide) is a dual GLP-1/GIP receptor agonist. It activates GLP-1 receptors plus GIP receptors. Most clinicians group it with the GLP-1 class.

How is Zepbound different from Mounjaro?

Same drug. Different brand names: Zepbound for weight loss and sleep apnea, Mounjaro for type 2 diabetes.

How much does Zepbound cost without insurance?

List price is $1,069/mo for autoinjector pens. Eli Lilly's LillyDirect program offers single-dose vials at $349/mo (lowest dose) to $499/mo (higher doses).